Uncategorized -
TransUnion Appoints Mohamed Abdelsadek Chief Global Solutions Officer
CHICAGO, March 10, 2025 (GLOBE NEWSWIRE) — Mohamed Abdelsadek has joined TransUnion (NYSE: TRU) as Executive Vice President and Chief […]
Uncategorized -
Record Results for Willis Lease Finance Corporation in 2024
COCONUT CREEK, Fla., March 10, 2025 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC”) today reported record annual […]
Uncategorized -
H World Group Limited Schedules Fourth Quarter and Full Year of 2024 Earnings Release on March 20, 2025
SINGAPORE and SHANGHAI, March 10, 2025 (GLOBE NEWSWIRE) — H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World”, […]
Uncategorized -
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
Five presentations affirm positive outcomes utilizing inhaled insulin An sNDA filing for Afrezza in pediatric population anticipated in 2025 DANBURY, […]
Uncategorized -
Synaptics Launches Ultra-Low-Power Wi-Fi/Bluetooth/802.15.4 Triple Combo SoC Family for Embedded Edge AI IoT
NUREMBERG, Germany, March 10, 2025 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) has extended its award-winning Veros™ Triple Combo connectivity […]
Uncategorized -
Synaptics Extends Edge AI Portfolio with High-Performance Adaptive MCUs for Multimodal Context-Aware Computing
NUREMBERG, Germany, March 10, 2025 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) has extended its award-winning Synaptics AstraTM AI-Native platform […]
Uncategorized -
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK®Q4 2024 Net Product Sales of […]
Uncategorized -
Beam Therapeutics Announces Pricing of Underwritten Offering
CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines […]
Uncategorized -
LexinFintech Holdings Ltd. to Report Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 18, 2025
SHENZHEN, China, March 10, 2025 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading credit technology-empowered […]
Uncategorized -
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, […]
